



Uptake of targeted therapies by income level, mCRC



Base sizes (number of patient record forms)	2015	2016	2017
<7,000 RMB/month	n=291	n=245	n=259
>10,000 RMB/month	n=118	n=250	n=380

Fig. 2: uptake of bevacizumab and cetuximab over time within drug-treated metastatic colorectal cancer patient records forms collected across 17 cities in China, by monthly household income level. (Source: Ipsos China Oncology Monitor 2015 – 2017; research conducted through pen and paper diaries March 2015 – September 2017)